Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 10, 2020 08:00 ET | Source: Advaxis, Inc.

Advaxis Reports Third Quarter Ended July 31, 2020 Financial Results and Provides a Business Update

Strategic expansion of ADXS-503 HOT program in NSCLC to explore potential to enhance and or restore sensitivity to checkpoint inhibitors Enrolling in Phase 1/2 Study efficacy expansion of ADXS-503...
September 04, 2020 16:30 ET | Source: Advaxis, Inc.

Advaxis Announces Resignation of Chief Financial Officer

PRINCETON, N.J., Sept. 04, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products...
August 27, 2020 08:00 ET | Source: Advaxis, Inc.

Advaxis to Present Corporate Overview at the LD Micro 500 Virtual Conference

PRINCETON, N.J., Aug. 27, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products,...
August 03, 2020 08:00 ET | Source: Advaxis, Inc.

Advaxis Announces Common Stock Purchase Agreement for up to $20 Million with Lincoln Park Capital

PRINCETON, N.J., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products...
June 23, 2020 08:00 ET | Source: Advaxis, Inc.

Advaxis to be Featured in “Grand Rounds: a Webinar in Biotech and Specialty Pharma,” Hosted by Alliance Global Partners

PRINCETON, N.J., June 23, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products,...
June 11, 2020 08:00 ET | Source: Advaxis, Inc.

Advaxis Reports Second Quarter Ended April 30, 2020 Financial Results and Provides a Business Update

Expanding Phase 1/2 Study of ADXS-503 in NSCLC based on sustained and durable clinical responses in first two patients from Part B combination arm with KEYTRUDA® Increasing patient enrollment in Part...
June 01, 2020 08:00 ET | Source: Advaxis, Inc.

Advaxis to Host Second Quarter Financial Results and Business Update Conference Call on Thursday, June 11, 2020

PRINCETON, N.J., June 01, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products,...
May 14, 2020 08:00 ET | Source: Advaxis, Inc.

Advaxis Announces Updated Positive Clinical and Biomarker Data from Ongoing Phase 1/2 ADXS-503 Trial in NSCLC

Sustained clinical benefit seen in patients treated with ADXS-503 in combination with KEYTRUDA® after 16 weeks, including a partial response and stable disease in patients who had most recently...
March 13, 2020 09:00 ET | Source: Advaxis, Inc.

Advaxis Reports First Quarter Ended January 31, 2020 Financial Results and Provides a Pipeline Update

PRINCETON, N.J., March 13, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products...
March 03, 2020 16:01 ET | Source: Advaxis, Inc.

Advaxis to Present at the 2020 LD Micro Virtual Conference

PRINCETON, N.J., March 03, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products,...